CJC-1295 (10 Vials of 5mg)
Origin: Keifei Bioresearch ,Thailand
Content: 10 Vials/ each vial 2 mg
Composition: Long-acting growth-hormone-releasing hormone (GHRH-analog)
CJC-1295 is a Long-acting growth-hormone-releasing hormone (GHRH) analog. Because of the long half-life and stability of the CJC-1295 analog,
it appears to become more and more popular.
CJC-1295 is a Long acting GHRH analog. Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin, is
a 44-amino acid peptide hormone produced in the hypothalamus by the arcuate nucleus. GHRH stimulates growth hormone (GH) secretion from the pituitary. GHRH is
released in a pulsatile manner, stimulating pulsatile release of GH respectively.
In addition, GHRH also promotes slow-wave sleep .
The active portion of this GRF or GHRH peptide can be found as a 29 amino acid long peptide and is appropriately named GHRH1-29. This pulsatile release of various peptides
is due to the negative feedback loop that is part of the hGH axis and controls the amount of hGH that your body produces to keep it in a homeostatic environment. Despite
the effectiveness of GHRH to stimulate growth hormone release there are a number of problems associated with using it in vivo. The most noteworthy problem is the half life
of the peptide, which has been shown to be ~7 minutes using advanced HPLC technologies that have proven to be very accurate. The reason for this relatively short half life
is due to an enzyme called dipeptidylaminopeptidase IV (DPP-IV), which has a high affinity for the amino acids Ala and Pro and in the case of GHRH it cleaves the 1 and 2
positions that consist of Tyr-Ala, creating GHRH3-29, an inactive form of the peptide. To prevent the problems associated with natural GHRH, pharmaceutical companies looked
at new ways to increase the half life and bioavailability of these smaller peptides with technologies that work far different than other technologies, such as PEGylation.
CJC-1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These
substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis
to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide
selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life. These substitutions are key in increasing the overall
half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days! Bioconjugation is a relatively newer
technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to
form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that
attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin.
Once the CJC-1295 molecule has attached itself to albumin, it is given an extended half life and bioavailability thanks to the albumin preventing enzymatic degredation and kidney
excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo and over 90% was stabilized after subcutaneous injection.
This means that you get more of what you paid for working for you. There was no DPP-IV degredation observed on CJC -1295 in any of the various experiments conducted.
Various experiments have been conducted to test the effectiveness of CJC -1295 in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases
in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection!
CJC-1295 is a long-lasting analog of GHRH and therefore only twice a week dosing is needed to keep GH levels elevated, However for extra GH release you may inject
CJC-1295 (long lasting GHRH) daily at the same time as you inject the GHRP-6.
But, is this combo of CJC-1295 and GHRP-6 even safe?
Safe? Unsafe? You can control the level of GH release through dosing. It is possible & easy to dose in such a way as to induce physiological levels of GH release.
Anytime you administer exogenic GH or induce high levels of GH release with CJC-1295/GHRP-6 you are administering a pharmacological dose.
I will say that CJC-1295 so far appears to result in more natural patterns of GH release (i.e. pulsation is preserved) as does GHRP-6 (pulse is amplified) because
the body in the end decides how much & in what manner it will produce GH.
With GH exogenically the body isn’t given the opportunity so with GH you end up with insulin resistance while with CJC-1295 anectdotally it so far appears you don’t.